All Articles

Amber Bio Raises $26 Million For Undruggable Diseases

August 5, 2023
x min read

Amber Bio, a San Francisco based developer of gene editing platforms to reach undruggable diseases, announced $26M in funding from a16z, Playground Global, Eli Lilly, Hummingbird Ventures and Pillar VC.

The big idea:

  • Amber Bio is developing an innovative RNA editing platform that aims to correct genetic mutations in a safe, reversible way
  • If successful, the technology would be able to edit thousands of of different, diverse mutations across patients with one single product
  • Current gene editing technology treats one single genetic mutation at a time, which is not scaleable for patients

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.